Where Will ISRG Stock Be in 5 Years?
Intuitive Surgical (NASDAQ:ISRG) is the innovative medical tech business behind…
Sell
17
BDRX Quote, Financials, Valuation and Earnings
Last price:
$2.13
Seasonality move
:
-22.97%
Day range:
$2.13 - $2.27
52-week range:
$2.03 - $92.00
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.73x
P/B ratio:
0.41x
Volume:
166K
Avg. volume:
1M
1-year change:
-95.03%
Market cap:
$1.9M
Revenue:
--
EPS (TTM):
-$25.93
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
BDRX
Biodexa Pharmaceuticals Plc
|
-- | -- | -- | -- | $17.94 |
|
AUTL
Autolus Therapeutics Plc
|
$24.1M | -$0.41 | 199.85% | -6.42% | $9.30 |
|
BCYC
Bicycle Therapeutics Plc
|
$7.1M | -$0.94 | -27.61% | -7.34% | $21.50 |
|
DBVT
DBV Technologies SA
|
$1.2M | -$0.22 | -- | -86.12% | $39.69 |
|
MREO
Mereo BioPharma Group Plc
|
$7.1M | -$0.01 | -100% | -75.07% | $3.45 |
|
NCNA
NuCana Plc
|
-- | -$0.01 | -- | -99.69% | $104.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
BDRX
Biodexa Pharmaceuticals Plc
|
$2.25 | $17.94 | $1.9M | -- | $0.00 | 0% | 0.73x |
|
AUTL
Autolus Therapeutics Plc
|
$1.39 | $9.30 | $369.9M | -- | $0.00 | 0% | 7.22x |
|
BCYC
Bicycle Therapeutics Plc
|
$7.00 | $21.50 | $485.6M | -- | $0.00 | 0% | 17.11x |
|
DBVT
DBV Technologies SA
|
$22.87 | $39.69 | $625.8M | -- | $0.00 | 0% | -- |
|
MREO
Mereo BioPharma Group Plc
|
$0.49 | $3.45 | $78.2M | -- | $0.00 | 0% | 153.66x |
|
NCNA
NuCana Plc
|
$3.10 | $104.00 | $12.9M | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
BDRX
Biodexa Pharmaceuticals Plc
|
-- | 3.608 | -- | 1.20x |
|
AUTL
Autolus Therapeutics Plc
|
55.06% | 2.916 | 74.96% | 4.83x |
|
BCYC
Bicycle Therapeutics Plc
|
1.04% | 1.504 | 1.21% | 9.36x |
|
DBVT
DBV Technologies SA
|
23.24% | -3.671 | 5.85% | 1.41x |
|
MREO
Mereo BioPharma Group Plc
|
0.85% | 1.603 | 0.12% | 8.09x |
|
NCNA
NuCana Plc
|
0.52% | -0.467 | 0.95% | 4.03x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
BDRX
Biodexa Pharmaceuticals Plc
|
-- | -- | -160.77% | -160.77% | -- | -- |
|
AUTL
Autolus Therapeutics Plc
|
-$10.8M | -$71.2M | -32.68% | -59.51% | -337.93% | -$79.9M |
|
BCYC
Bicycle Therapeutics Plc
|
$9.9M | -$72.9M | -33.96% | -34.37% | -624.9% | -$71.3M |
|
DBVT
DBV Technologies SA
|
-$4.3M | -$36.9M | -211.46% | -280.59% | -- | -$32.5M |
|
MREO
Mereo BioPharma Group Plc
|
-- | -$10.3M | -67.41% | -70.81% | -2099.86% | -$7.3M |
|
NCNA
NuCana Plc
|
-$93K | -$4.8M | -281.73% | -286.82% | -- | $1.5M |
Biodexa Pharmaceuticals Plc vs. Competitors
-
Which has Higher Returns BDRX or AUTL?
Autolus Therapeutics Plc has a net margin of -- compared to Biodexa Pharmaceuticals Plc's net margin of -373.3%. Biodexa Pharmaceuticals Plc's return on equity of -160.77% beat Autolus Therapeutics Plc's return on equity of -59.51%.
Company Gross Margin Earnings Per Share Invested Capital BDRXBiodexa Pharmaceuticals Plc-- -- $6M AUTLAutolus Therapeutics Plc-51.21% -$0.30 $590.6M -
What do Analysts Say About BDRX or AUTL?
Biodexa Pharmaceuticals Plc has a consensus price target of $17.94, signalling upside risk potential of 7804.5%. On the other hand Autolus Therapeutics Plc has an analysts' consensus of $9.30 which suggests that it could grow by 569.07%. Given that Biodexa Pharmaceuticals Plc has higher upside potential than Autolus Therapeutics Plc, analysts believe Biodexa Pharmaceuticals Plc is more attractive than Autolus Therapeutics Plc.
Company Buy Ratings Hold Ratings Sell Ratings BDRXBiodexa Pharmaceuticals Plc1 0 0 AUTLAutolus Therapeutics Plc9 0 0 -
Is BDRX or AUTL More Risky?
Biodexa Pharmaceuticals Plc has a beta of 0.952, which suggesting that the stock is 4.8% less volatile than S&P 500. In comparison Autolus Therapeutics Plc has a beta of 2.012, suggesting its more volatile than the S&P 500 by 101.185%.
-
Which is a Better Dividend Stock BDRX or AUTL?
Biodexa Pharmaceuticals Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Autolus Therapeutics Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Biodexa Pharmaceuticals Plc pays -- of its earnings as a dividend. Autolus Therapeutics Plc pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BDRX or AUTL?
Biodexa Pharmaceuticals Plc quarterly revenues are --, which are smaller than Autolus Therapeutics Plc quarterly revenues of $21.1M. Biodexa Pharmaceuticals Plc's net income of -- is lower than Autolus Therapeutics Plc's net income of -$78.6M. Notably, Biodexa Pharmaceuticals Plc's price-to-earnings ratio is -- while Autolus Therapeutics Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biodexa Pharmaceuticals Plc is 0.73x versus 7.22x for Autolus Therapeutics Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BDRXBiodexa Pharmaceuticals Plc0.73x -- -- -- AUTLAutolus Therapeutics Plc7.22x -- $21.1M -$78.6M
-
Which has Higher Returns BDRX or BCYC?
Bicycle Therapeutics Plc has a net margin of -- compared to Biodexa Pharmaceuticals Plc's net margin of -503.67%. Biodexa Pharmaceuticals Plc's return on equity of -160.77% beat Bicycle Therapeutics Plc's return on equity of -34.37%.
Company Gross Margin Earnings Per Share Invested Capital BDRXBiodexa Pharmaceuticals Plc-- -- $6M BCYCBicycle Therapeutics Plc85.04% -$0.85 $625M -
What do Analysts Say About BDRX or BCYC?
Biodexa Pharmaceuticals Plc has a consensus price target of $17.94, signalling upside risk potential of 7804.5%. On the other hand Bicycle Therapeutics Plc has an analysts' consensus of $21.50 which suggests that it could grow by 207.14%. Given that Biodexa Pharmaceuticals Plc has higher upside potential than Bicycle Therapeutics Plc, analysts believe Biodexa Pharmaceuticals Plc is more attractive than Bicycle Therapeutics Plc.
Company Buy Ratings Hold Ratings Sell Ratings BDRXBiodexa Pharmaceuticals Plc1 0 0 BCYCBicycle Therapeutics Plc6 4 0 -
Is BDRX or BCYC More Risky?
Biodexa Pharmaceuticals Plc has a beta of 0.952, which suggesting that the stock is 4.8% less volatile than S&P 500. In comparison Bicycle Therapeutics Plc has a beta of 1.524, suggesting its more volatile than the S&P 500 by 52.42%.
-
Which is a Better Dividend Stock BDRX or BCYC?
Biodexa Pharmaceuticals Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bicycle Therapeutics Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Biodexa Pharmaceuticals Plc pays -- of its earnings as a dividend. Bicycle Therapeutics Plc pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BDRX or BCYC?
Biodexa Pharmaceuticals Plc quarterly revenues are --, which are smaller than Bicycle Therapeutics Plc quarterly revenues of $11.7M. Biodexa Pharmaceuticals Plc's net income of -- is lower than Bicycle Therapeutics Plc's net income of -$58.7M. Notably, Biodexa Pharmaceuticals Plc's price-to-earnings ratio is -- while Bicycle Therapeutics Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biodexa Pharmaceuticals Plc is 0.73x versus 17.11x for Bicycle Therapeutics Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BDRXBiodexa Pharmaceuticals Plc0.73x -- -- -- BCYCBicycle Therapeutics Plc17.11x -- $11.7M -$58.7M
-
Which has Higher Returns BDRX or DBVT?
DBV Technologies SA has a net margin of -- compared to Biodexa Pharmaceuticals Plc's net margin of --. Biodexa Pharmaceuticals Plc's return on equity of -160.77% beat DBV Technologies SA's return on equity of -280.59%.
Company Gross Margin Earnings Per Share Invested Capital BDRXBiodexa Pharmaceuticals Plc-- -- $6M DBVTDBV Technologies SA-- -$1.21 $68.9M -
What do Analysts Say About BDRX or DBVT?
Biodexa Pharmaceuticals Plc has a consensus price target of $17.94, signalling upside risk potential of 7804.5%. On the other hand DBV Technologies SA has an analysts' consensus of $39.69 which suggests that it could grow by 73.26%. Given that Biodexa Pharmaceuticals Plc has higher upside potential than DBV Technologies SA, analysts believe Biodexa Pharmaceuticals Plc is more attractive than DBV Technologies SA.
Company Buy Ratings Hold Ratings Sell Ratings BDRXBiodexa Pharmaceuticals Plc1 0 0 DBVTDBV Technologies SA4 0 1 -
Is BDRX or DBVT More Risky?
Biodexa Pharmaceuticals Plc has a beta of 0.952, which suggesting that the stock is 4.8% less volatile than S&P 500. In comparison DBV Technologies SA has a beta of -1.166, suggesting its less volatile than the S&P 500 by 216.581%.
-
Which is a Better Dividend Stock BDRX or DBVT?
Biodexa Pharmaceuticals Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. DBV Technologies SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Biodexa Pharmaceuticals Plc pays -- of its earnings as a dividend. DBV Technologies SA pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BDRX or DBVT?
Biodexa Pharmaceuticals Plc quarterly revenues are --, which are smaller than DBV Technologies SA quarterly revenues of --. Biodexa Pharmaceuticals Plc's net income of -- is lower than DBV Technologies SA's net income of -$33M. Notably, Biodexa Pharmaceuticals Plc's price-to-earnings ratio is -- while DBV Technologies SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biodexa Pharmaceuticals Plc is 0.73x versus -- for DBV Technologies SA. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BDRXBiodexa Pharmaceuticals Plc0.73x -- -- -- DBVTDBV Technologies SA-- -- -- -$33M
-
Which has Higher Returns BDRX or MREO?
Mereo BioPharma Group Plc has a net margin of -- compared to Biodexa Pharmaceuticals Plc's net margin of -2923.31%. Biodexa Pharmaceuticals Plc's return on equity of -160.77% beat Mereo BioPharma Group Plc's return on equity of -70.81%.
Company Gross Margin Earnings Per Share Invested Capital BDRXBiodexa Pharmaceuticals Plc-- -- $6M MREOMereo BioPharma Group Plc14% -$0.04 $47M -
What do Analysts Say About BDRX or MREO?
Biodexa Pharmaceuticals Plc has a consensus price target of $17.94, signalling upside risk potential of 7804.5%. On the other hand Mereo BioPharma Group Plc has an analysts' consensus of $3.45 which suggests that it could grow by 600.69%. Given that Biodexa Pharmaceuticals Plc has higher upside potential than Mereo BioPharma Group Plc, analysts believe Biodexa Pharmaceuticals Plc is more attractive than Mereo BioPharma Group Plc.
Company Buy Ratings Hold Ratings Sell Ratings BDRXBiodexa Pharmaceuticals Plc1 0 0 MREOMereo BioPharma Group Plc4 2 0 -
Is BDRX or MREO More Risky?
Biodexa Pharmaceuticals Plc has a beta of 0.952, which suggesting that the stock is 4.8% less volatile than S&P 500. In comparison Mereo BioPharma Group Plc has a beta of 0.358, suggesting its less volatile than the S&P 500 by 64.214%.
-
Which is a Better Dividend Stock BDRX or MREO?
Biodexa Pharmaceuticals Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Mereo BioPharma Group Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Biodexa Pharmaceuticals Plc pays -- of its earnings as a dividend. Mereo BioPharma Group Plc pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BDRX or MREO?
Biodexa Pharmaceuticals Plc quarterly revenues are --, which are smaller than Mereo BioPharma Group Plc quarterly revenues of --. Biodexa Pharmaceuticals Plc's net income of -- is lower than Mereo BioPharma Group Plc's net income of -$7M. Notably, Biodexa Pharmaceuticals Plc's price-to-earnings ratio is -- while Mereo BioPharma Group Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biodexa Pharmaceuticals Plc is 0.73x versus 153.66x for Mereo BioPharma Group Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BDRXBiodexa Pharmaceuticals Plc0.73x -- -- -- MREOMereo BioPharma Group Plc153.66x -- -- -$7M
-
Which has Higher Returns BDRX or NCNA?
NuCana Plc has a net margin of -- compared to Biodexa Pharmaceuticals Plc's net margin of --. Biodexa Pharmaceuticals Plc's return on equity of -160.77% beat NuCana Plc's return on equity of -286.82%.
Company Gross Margin Earnings Per Share Invested Capital BDRXBiodexa Pharmaceuticals Plc-- -- $6M NCNANuCana Plc-- -$0.13 $35.1M -
What do Analysts Say About BDRX or NCNA?
Biodexa Pharmaceuticals Plc has a consensus price target of $17.94, signalling upside risk potential of 7804.5%. On the other hand NuCana Plc has an analysts' consensus of $104.00 which suggests that it could grow by 670867.74%. Given that NuCana Plc has higher upside potential than Biodexa Pharmaceuticals Plc, analysts believe NuCana Plc is more attractive than Biodexa Pharmaceuticals Plc.
Company Buy Ratings Hold Ratings Sell Ratings BDRXBiodexa Pharmaceuticals Plc1 0 0 NCNANuCana Plc0 1 0 -
Is BDRX or NCNA More Risky?
Biodexa Pharmaceuticals Plc has a beta of 0.952, which suggesting that the stock is 4.8% less volatile than S&P 500. In comparison NuCana Plc has a beta of 1.602, suggesting its more volatile than the S&P 500 by 60.248%.
-
Which is a Better Dividend Stock BDRX or NCNA?
Biodexa Pharmaceuticals Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NuCana Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Biodexa Pharmaceuticals Plc pays -- of its earnings as a dividend. NuCana Plc pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BDRX or NCNA?
Biodexa Pharmaceuticals Plc quarterly revenues are --, which are smaller than NuCana Plc quarterly revenues of --. Biodexa Pharmaceuticals Plc's net income of -- is lower than NuCana Plc's net income of -$378.9K. Notably, Biodexa Pharmaceuticals Plc's price-to-earnings ratio is -- while NuCana Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biodexa Pharmaceuticals Plc is 0.73x versus -- for NuCana Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BDRXBiodexa Pharmaceuticals Plc0.73x -- -- -- NCNANuCana Plc-- -- -- -$378.9K
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Kratos Stock a Good Investment?
UAV and hypersonic system defense contractor Kratos (NASDAQ:KTOS) has swung…
Is Palantir Stock Going to Crash?
AI and data analytics major Palantir (NASDAQ:PLTR) has become something…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Sell
50
Is GOOGL Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Alerts
Buy
52
CVLT alert for Jan 27
Commvault Systems, Inc. [CVLT] is down 31.22% over the past day.
Buy
73
BNAI alert for Jan 27
Brand Engagement Network, Inc. [BNAI] is down 16.85% over the past day.
Buy
71
SANM alert for Jan 27
Sanmina Corp. [SANM] is down 21.58% over the past day.
